Astellas partners with CUOG to advance uro-oncology research in Canada

Astellas partners with CUOG to advance uro-oncology research in Canada 
MARKHAM, ON, April 17, 2013 /CNW/ - Genitourinary cancer research in Canada 
will receive additional funding thanks to a new research collaboration between 
the Canadian Urologic Oncology Group (CUOG) and Astellas Pharma Canada, Inc. 
(Astellas). 
This year, Astellas has pledged $50,000 to further Canadian investigators' 
peer-reviewed research into finding medicines and cures for urological 
disorders, focusing specifically on prostate cancer. 
The CUOG/Astellas Research Awards in prostate cancer will range between 
$10,000 and $25,000 each, depending on the number of applicants received, and 
are in addition to Astellas' multi-year commitment to the Canadian urology 
community through the CUA Astellas Research Grant program. 
"For over 20 years, the Canadian Urologic Oncology Group has promoted research 
by students, residents and fellows through annual CUOG awards. Under the 
supervision of CUOG members, students have conducted research that has led to 
some extremely valuable findings and, in many cases, served as the foundation 
for larger projects and research careers," says Dr. Fred Saad, Chair of the 
National Cancer Institute of Canada G-U Group and the Canadian Urologic 
Oncology Group. "We are very pleased to be able to increase the amount of 
money available for CUOG awards due to additional funding provided by Astellas 
Pharma Canada." 
Urology continues to be a priority therapeutic area for Astellas and the 
company is proud to support the efforts of the Canadian urology community 
through its ongoing contributions to investigator research and patient 
programs. 
"Innovations that result from discovery research can potentially have a great 
impact on patients in the future," says Michael Tremblay, President, Astellas 
Pharma Canada. "We are honoured to contribute to advancing uro-oncology 
research, with the hope that one day it will produce a cure for genitourinary 
cancers." 
Applications for the CUOG/Astellas Research Awards are due May 1, 2013 and the 
recipients will be announced at the annual CUOG meeting on June 22. 
For more information, please visit CUOG's website, www.cuog.org. 
About the Canadian Urologic Oncology Group (CUOG) 
The Canadian Urologic Oncology Group (CUOG) is a clinical research 
investigator network of leading academic and community based urologists, 
medical oncologists, and radiation oncologists, committed to furthering 
genitourinary (GU) cancer research in Canada. 
CUOG pursues clinical trials in concert with the pharmaceutical industry to 
find medicines and cures to tackle urological disorders including, but not 
restricted to: 


    --  Prostate cancer
    --  Bladder cancer
    --  Renal cancer
    --  Testicular cancer

More information about CUOG can be found at www.cuog.org.

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian 
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical 
company dedicated to improving the health of people around the world through 
the provision of innovative and reliable pharmaceutical products.

The organization is committed to becoming a global category leader in focused 
areas by combining outstanding R&D and marketing capabilities. In Canada, 
Astellas has an intense commercial focus on five therapeutic areas - Urology, 
Immunology, Infectious Disease, Dermatology and Oncology.

For more information about Astellas Pharma Canada, Inc., please visit the 
corporate website: www.astellas.ca

Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905) 
946-5621 naomi.cote@astellas.com

SOURCE: Astellas Pharma Canada, Inc.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/17/c5378.html

CO: Astellas Pharma Canada, Inc.
ST: Ontario
NI: MTC HEA 

-0- Apr/17/2013 12:30 GMT


 
Press spacebar to pause and continue. Press esc to stop.